 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Razi Cov Pars / Razi Vaccine and Serum Research Institute
Clinical, Journal: Safety and Immunogenicity of Intranasal Razi Cov Pars as a COVID-19 Booster Vaccine in Adults: Promising Results from a Groundbreaking Clinical Trial. (Pubmed Central) - Nov 26, 2024
We detected no serious adverse reactions or anaphylaxis and all adverse events resolved completely during the follow-up period and were similar in both groups. Intranasal RCP is safe, stimulates the respiratory mucosal immunity, and could be a booster on various COVID-19 vaccines and be effective against new virus variants.
- | Covilo (BBIBP-CorV) / Wuhan Institute of Virology, Sinopharm, Jcovden (COVID-19 vaccine (Ad26.COV2-S [recombinant])) / J&J, Razi Cov Pars / Razi Vaccine and Serum Research Institute
Journal: Analysis of immunological and biochemical parameters after booster dose vaccination using protein-based and inactivated virus vaccine for safety. (Pubmed Central) - Nov 25, 2024
Intranasal RCP is safe, stimulates the respiratory mucosal immunity, and could be a booster on various COVID-19 vaccines and be effective against new virus variants. Considering rare side effects is essential in evaluating COVID-19 vaccines, especially those associated with ChAdOx1-S (AstraZeneca) and Ad26.COV2.S (Janssen), including blood clotting and idiopathic thrombocytopenia...Participants receiving the Razi-CoV-Pars booster after Sinopharm/BBIBP-CorV showed significantly higher antibody levels (Wuhan
- || Covilo (BBIBP-CorV) / Wuhan Institute of Virology, Sinopharm
Clinical, Journal: Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial. (Pubmed Central) - Feb 25, 2024
BBIBP-CorV and RCP vaccines as booster doses are safe and provide a strong immune response that is more robust when the RCP vaccine is used. Heterologous vaccines are preferred as booster doses.
- | Razi Cov Pars / Razi Vaccine and Serum Research Institute
Preclinical, Journal: Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models. (Pubmed Central) - Jun 14, 2022
Of the three tested vaccine regimens, the middle dose of the vaccine showed the best protective immune parameters. This vaccine with heterologous prime-boost vaccination method can be a good candidate to control the viral infection and its spread by stimulating central and mucosal immunity.
- ||| Razi Cov Pars / Razi Vaccine and Serum Research Institute
Clinical: there is a vaccine developed in Iran, Razi CoV Pars, only in use in Iran so far that is 3 doses. 1st dose IM, 2nd dose IM, 3rd dose intranasal. It is a protein subunit vaccine so maybe won't get the same robust initial titers, but adding the intranasal at 21 days is brilliant (Twitter) - Dec 12, 2021